Low Incidence of Discontinuation Due to AEs1-3
Header | ||
---|---|---|
Header | Header | Header |
Content | Content | Content |
Content | Content | Content |
Content | Content | Content |
Content | Content | Content |
Content | Content | Content |
Content | Content | Content |
Content | Content | Content |
Content | Content | Content |
Integrated safety summary of the FOCUS 1 and FOCUS 2 trials:
Comparison of specific treatment-emergent AEs occurring with a frequency of >1% (with a difference of ≥0.5% among treatment groups).4,†
*Comparators from ZINFORO® clinical trials for the treatment of CAP and cSSTI.2
†Please refer to the full Prescribing Information for the complete list of AEs.
AE, adverse event; CAP, community-acquired pneumonia; cSSTI, complicated skin and soft tissue infection; FOCUS, ceftaroline community-acquired pneumonia trial versus ceftriaxone in hospitalised patients.
References:
Proven clinical efficacy in patients with
CAP and cSSTI
ZINFORO® in the treatment of CAP and cSSTI
These pages are not intended for patients or for members of the general public. The web pages contain promotional content.
If you select 'No', you will be redirected to Pfizer.co.in
For more details on, Who is a Registered Medical Practitioner*, please visit
https://cdsco.gov.in/opencms/export/sites/CDSCO_WEB/Pdf-documents/acts_rules/2016DrugsandCosmeticsAct1940Rules1945.pdf , Page No. 39, Rule 2 part (ee), last accessed on 13th September 2019.
Address: The Capital, A Wing, 1802, 18th Floor, Plot No. C-70, 'G' Block, Bandra Kurla Complex, Bandra East, Mumbai - 400051.